X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Financing will be used to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy.
Lead Product(s): EO2401
Therapeutic Area: Oncology Product Name: EO2401
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Recipient: Enterome
Deal Size: $52.6 Million Upfront Cash: Undisclosed
Deal Type: Financing June 25, 2020
Details:
Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply.
Lead Product(s): AZD1222
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2020
Details:
The funding will continue the clinical development of the company's current pipeline as well as the extension to other indications in oncology.
Lead Product(s): MaaT013
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: MaaT Pharma
Deal Size: $19.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
